Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group.

Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4.

PMID:
23294853
2.

Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.

Hervonen P, Joensuu H, Joensuu T, Ginman C, McDermott R, Harmenberg U, Nyandoto P, Luukkaala T, Hemminki A, Zaitsev I, Heikkinen M, Nilsson S, Luukkaa M, Lehtinen I, Kellokumpu-Lehtinen PL.

Anticancer Res. 2012 Mar;32(3):953-6. Erratum in: Anticancer Res. 2012 Sep;32(9):4169. multiple author names corrected.

PMID:
22399616
3.

Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck.

Luukkaa M, Jokilehto T, Kronqvist P, Vahlberg T, Grénman R, Jaakkola P, Minn H.

Int J Radiat Biol. 2009;85(10):900-8. doi: 10.1080/09553000903074104.

PMID:
19639506
4.

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S.

Neoplasia. 2009 Jul;11(7):629-36.

5.

Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival.

Rautava J, Luukkaa M, Heikinheimo K, Alin J, Grenman R, Happonen RP.

Oral Oncol. 2007 Oct;43(9):911-9. Epub 2007 Jan 25.

PMID:
17257885
6.

Oral tongue carcinoma and its treatment in Finland.

Mäkitie AA, Koivunen P, Keski-Säntti H, Törnwall J, Pukkila M, Laranne J, Luukkaa M, Vuola J, Joensuu T, Kajanti M, Grénman R.

Eur Arch Otorhinolaryngol. 2007 Mar;264(3):263-7. Epub 2006 Sep 21.

PMID:
17021781
7.

Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.

Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM.

Clin Cancer Res. 2006 Feb 15;12(4):1080-7.

8.

Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.

Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, Grénman R.

Head Neck. 2006 Mar;28(3):225-34.

PMID:
16302191
9.

Treatment of squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx--an analysis of 174 patients in south western Finland.

Luukkaa M, Minn H, Aitasalo K, Kronqvist P, Kulmala J, Pyrhönen S, Grénman R.

Acta Oncol. 2003;42(7):756-62.

PMID:
14690162
10.

Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region.

Maula SM, Luukkaa M, Grénman R, Jackson D, Jalkanen S, Ristamäki R.

Cancer Res. 2003 Apr 15;63(8):1920-6.

11.

Neodymium YAG contact laser in the treatment of cancer of the mobile tongue.

Luukkaa M, Aitasalo K, Pulkkinen J, Lindholm P, Valavaara R, Grénman R.

Acta Otolaryngol. 2002 Apr;122(3):318-22.

PMID:
12030583

Supplemental Content

Loading ...
Support Center